Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study

Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study

Abstract Objective Subcutaneous ocrelizumab is being developed to provide treatment flexibility and additional choice to patients with multiple sclerosis. OCARINA I (NCT03972306) is an open‐label, multicenter, Phase 1b, dose‐finding study to investigate the pharmacokinetics, safety, tolerability, an...

Full description

Saved in:
Bibliographic Details
Main Authors: Scott D. Newsome, Lawrence Goldstick, Derrick S. Robertson, James D. Bowen, Robert T. Naismith, Ben Townsend, Catarina Figueiredo, Heidemarie Kletzl, Mylene Giraudon, Oscar Bortolami, Dusanka Zecevic, Caroline Giacobino, Susanne Clinch, Yun‐An Shen, Gurpreet Deol-Bhullar, Robert A. Bermel
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Annals of Clinical and Translational Neurology
Online Access:https://doi.org/10.1002/acn3.52229
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items